Summary of "PEPTIDES RANKED! Growth Hormone, IGF-1, Insulin, BPC-157, TB-500, Mots-C, MK-677, Follistatin, Etc"

Overview / Context

The hosts discuss an “anabolic peptides tier list” (S → F) covering:
- Growth hormone (GH)
- Insulin
- IGF-related drugs/peptides
- Various other peptides/ancillaries
They also mention upcoming episodes focused on cycle design (training/nutrition/supplementation from beginner through “turn pro”).

Key wellness / self-care + productivity-style takeaways (as discussed)

While much of the episode is pharmacology, several behavioral harm-reduction and performance-enabler themes come up:

Use bloodwork as an essential safeguard
- GH/IGF/insulin-related use should be verified with labs (“imperative”) to ensure the substance is actually present and affecting you as expected.
- Insulin is specifically framed as requiring monitoring of health parameters and insulin sensitivity, not just “training gains.”
Ramp dosing slowly rather than jumping
- For GH, they recommend gradual dose escalation to improve tolerability and reduce side effects.
- Sudden large jumps were described as increasing risk (example given: electrolyte issues / nerve symptoms and tolerability concerns).
Electrolyte management + supplement awareness
- GH discussion included managing magnesium/potassium to avoid nerve/carpal-tunnel type symptoms.
- Taurine was suggested as something some people tolerate better at higher GH dosing (vs going too high too quickly).
Timing strategies to reduce metabolic issues
- They advise against morning-only GH for those concerned about glucose metabolism, arguing GH effects via IGF and longer biological windows mean meal timing often matters less than people think—but glucose control does.
- For peptides/secretagogues, they emphasize that some require more nuanced timing because insulin/food presence can change feedback loops.
Training performance depends on energy management, not “more calories = more muscle”
- Muscle growth still requires energy for protein translation, but excessive caloric swings can create problems.
- Suggested approach: small caloric adjustments (roughly ~10% or a few hundred calories) while monitoring training/energy/body composition.

Main wellness + productivity tips (from the tier-list discussion)

1) Growth Hormone (GH) ranking + practical advice

Tier stance
- S-tier for GH (both solo and combined with anabolic steroids).
- Generics are discussed as lower (around C–B range depending on quality) due to absorption/binders/fillers and inconsistent effects.
Dose/tolerability strategy
- Slow ramp-up over time.
- Manage electrolytes (Mg/K) and consider taurine.
- Avoid abrupt jumps that can worsen side effects (e.g., water retention/carpal-tunnel-type symptoms).
Administration + glucose-metabolism claim
- Preference expressed for night dosing (single injection, not splitting).
- Rationale: taking it earlier could worsen glucose metabolism; the “timing window” argument is based on absorption/IGF dynamics.
Generic vs pharma
- Generics may be ~50% absorbed vs pharma; therefore dosing/expectations differ and research is limited.
Dilution/safety (harm reduction)
- Use bacteriostatic water for reconstitution/dilution when not using the full vial.
- Avoid using saline.
- Using sterile water only if using the entire bottle right away (risk of bacterial growth).

2) GH secretagogues / releasing peptides (ranked low)

Classified as lower than GH itself, mainly due to limited/economics and uncertain real-world output.
Key framework they use:
- Rate limit = pituitary function (not wallet/pinning convenience).
- Timing becomes more important because feedback loops (insulin/somatostatin/IGF1) affect secretion.
Cost-effectiveness logic
- It’s often not worth paying for secretagogues if the output is small compared with injectable GH.
MK-677 (as discussed)
- Discussed as potentially moving toward pharmaceutical status and as useful mainly when appetite/food intake is the limiting factor.
- Common side effects mentioned: increased appetite and weird dreams.
- Generally viewed as better value than many secretagogues, especially given cost.

3) IGF-1 / related agents (injection forms discussed)

Overall: many are ranked F-tier
- Hosts describe poor consistency, questionable sourcing accuracy, and limited bloodwork impact in many cases.
In particular: IGF-1 analogs (LR3/Des)
- Positioned as inefficient/overhyped relative to injected GH/IGF strategies.
- Bloodwork often doesn’t show strong serum changes despite anecdotal “feeling fuller” reports.
INRCEX (IGF-1)
- Discussed as highly effective but hard to access/expensive.
- They argue it can be near “break-even” financially vs high-dose pharma GH in some scenarios, but sourcing availability is the major constraint.

4) Insulin (ranked as niche / not for most)

Overall stance
- Treated as end-stage glucose/nutrient-partitioning support, not a must-have for most users.
Rank
- Generally D-tier (and/or lower than many other options) because:
  - It’s not “wildly anabolic alone”
  - It increases risk—especially hypoglycemia and sleep disruption with late dosing.
Timing guidance (safety framing)
- Rapid-acting insulin offers limited windows; later peaks can disturb sleep via hypoglycemia.
- More “usable” timing windows discussed as morning/early evening and post-workout (with caution).
Conditional approval
- Only for those who “need it” (high caloric intake/advanced size targets) and can monitor labs and health markers.

5) Healing peptides (BPC-157, TB-500): injury recovery focus

Top wellness/recovery ranking
- S-tier for both.
Primary use-case
- Tendon/connective tissue injury healing, inflammation reduction, and recovery acceleration.
Evidence framing
- Hosts cite a deep dive into studies and argue TB-500/BPC-157 have strong healing data (more so than “performance gains”).
Mechanism narrative
- Angiogenesis regulation and GH receptor-related effects (BPC-157 framed as upregulating GH receptor density).
Important safety/nuance
- Potential cancer risk concerns were mentioned via angiogenesis/androgenesis, but they suggest some targeting/directionality as part of the mechanism (still not deeply established in humans).

Tier list (as stated by the speakers)

S-tier
- Pharma growth hormone
- INRCEX (pharmaceutical IGF-1)
A-tier (healing peptides / mitochondria-related items)
- BPC-157
- TB-500
- MOTS-c (Mod C) (also discussed as highly beneficial for mitochondrial performance)
B-tier
- BPC-157 and TB-500 were also referenced in the main tier confirmations (the convo has some overlap in where they land, but final recap places healing peptides in the A-tier block)
C-tier
- Generic GH
- MK-677
D-tier
- Insulin
E/F-tier
- F-tier: IGF-1 LR3, IGF-1 DES, mechano growth factor (MGF), fostatrin/myostatin inhibitors (e.g., “myostatin inhibition” candidates), A031/A083
- E-tier / TBD: EPO (placed as “to be determined” / too risky / nuanced)